ImmunoScience, Inc. Email Format
Biotechnology ResearchUnited States11-50 Employees
ImmunoScience, Inc. is a biotechnology research and development company specializing in the diagnosis and treatment of HIV. ImmunoScience's flagship product is Contre Vir™, a recombinant, live, attenuated therapeutic vaccine for the treatment and potential cure of AIDS and the HIV infection. Contre Vir™ has shown a very high level of success in pre-clinical studies and pilot clinical trials. Further studies are in final planning stages in several countries where interest is extremely high. ImmunoScience has several patents for Contre Vir™ across the globe and is expected to start Phase I clinical trials for Contre Vir™ in the very near future. The preliminary work for these trials is already underway in the United States, Belgium, Ghana and Uganda. ImmunoScience considers this invention to be a ground-breaking step forward in the fight against AIDS and HIV.